

Reblozyl[®]
(luspatercept-aamt)
for injection 25mg • 75mg

 Bristol Myers Squibb[®]
Access Support[®] >
Your patient. Our commitment.

A REFERENCE GUIDE TO
**Reimbursement and
Coding for REBLOZYL[®]** >
(luspatercept-aamt)

To view authorized distributors/specialty pharmacies for REBLOZYL, visit BMSAccessSupport.com.
Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

Indications

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Select Important Safety Information

WARNINGS AND PRECAUTIONS

Thrombosis/Thromboembolism

In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) of REBLOZYL-treated patients. TEEs included deep vein thrombosis, pulmonary embolus, portal vein thrombosis, and ischemic stroke. Patients with known risk factors for thromboembolism (splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients at increased risk of TEE. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Bristol Myers Squibb Is Committed to Helping Support Access

This brochure is designed to help appropriate patients get access to our medications by providing helpful reimbursement information for healthcare offices. Healthcare benefits vary significantly; therefore, it is important that oncology offices verify each patient's insurance coverage prior to initiating therapy.

Table of Contents

NDC Information and Storage	4
HCPCS and Revenue Codes	5
Current Procedural Terminology (CPT) Codes	6
ICD-10-CM Diagnosis Codes	7
5010 Electronic Transaction Coding	9
Coding and Billing Units	10
Dosage and Administration	
In Beta Thalassemia	12
In MDS Associated Anemia	14
General Reimbursement Information	19
Important Safety Information	21

Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and the best coding practices. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

National Drug Code (NDC) Information and Storage

The NDCs for REBLOZYL, listed below, are often necessary in addition to the appropriate J code when filing a claim for reimbursement.

NDCs for REBLOZYL¹

REBLOZYL injection 25 mg/vial
25 mg lyophilized powder in a
single-dose vial for reconstitution

59572-0711-01



REBLOZYL injection 75 mg/vial
75 mg lyophilized powder in a
single-dose vial for reconstitution

59572-0775-01

The red zero (red text) converts the 10-digit NDC to the 11-digit NDC. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Storage¹

Store vials refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in original carton to protect from light. Do not freeze.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Healthcare Common Procedure Coding System (HCPCS) and Revenue Codes

HCPCS codes are used for billing drugs and services to Medicare, Medicaid, and the commercial payer.

Recommended HCPCS Code for REBLOZYL ²	
HCPCS Code	Description
J0896	Injection, luspatercept-aamt, 0.25 mg

Billing Unit Conversion ³			
0.25 mg	1 unit	25-mg vial	100 units
		75-mg vial	300 units

Depending on payer preferences for billing and coding, the billing unit conversion for claim submission may vary. Therefore, the provider should confirm preference with the payer prior to submitting.

The information contained herein is not intended to provide specific coding and reimbursement advice for any specific patient or situation. You should check with your coding specialist to ensure appropriate submissions.

It is important to note that for accurate reimbursement, any quantity of REBLOZYL that is discarded after treatment should be coded with a **JW modifier**. A JW modifier indicates unused drug or biological from a single-use vial in the event that the entire dose/quantity is not administered and the remainder is discarded.³

Use the following claim formats when REBLOZYL is administered to patients on an outpatient basis and billed to health plans:

- Physician office: CMS-1500 (paper format) or ASC 837P (electronic format)
- Hospital outpatient: UB-04 (CMS-1450) (paper format) or ASC 837I (electronic format)

All the coding information presented is applicable to outpatient procedures only. Please see pages 10 and 11 for more information.

Revenue Codes ⁴ That May Be Used for Administration of REBLOZYL (Hospital Use)	
Revenue Code	Description
0636	Drugs requiring detailed coding
0250	Pharmacy
0331	Chemo admin, injected

Revenue codes categorize services in the hospital by revenue center. Medicare and most Medicaid and private payer claims must include revenue codes in field 42 of form UB-04 (CMS-1450).

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Current Procedural Terminology (CPT)* Codes

CPT codes are used to indicate which medical services and procedures were performed on a patient and/or how a drug or medical supply was administered.

The CPT codes that may be appropriate for administration of REBLOZYL appear in the table below.

Recommended CPT Codes for REBLOZYL ⁵	
CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

Please contact the payer or BMS Access Support® for additional coding information regarding REBLOZYL.

*CPT codes and descriptions only are ©2026 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

ICD-10-CM Diagnosis Codes

ICD-10-CM diagnosis codes are used to identify a patient's diagnosis. On October 1, 2015, the newest version of these codes, ICD-10-CM, was implemented throughout the United States. This version replaces the previous version, ICD-9-CM.

- The ICD-10-CM diagnosis codes contain **categories**, **subcategories**, and **codes**. Characters for categories, subcategories, and codes may be letters or numerals
- **All categories** are 3 characters
- **Subcategories** are either 4 or 5 characters
- **Codes** may be 3, 4, 5, 6, or 7 characters

The ICD-10-CM diagnosis codes for the labeled indications for REBLOZYL are provided on page 8 by Bristol Myers Squibb and should be verified with the payer. Some health plan and Medicare insurers may specify which codes are covered under their policies. Please code to the level of specificity documented in the medical record. For additional coding questions, call BMS Access Support® at **1-800-861-0048** or visit www.BMSAccessSupport.com.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at **1-800-861-0048**, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

ICD-10-CM Diagnosis Codes

ICD-10-CM Diagnosis Codes for Beta Thalassemia⁶

ICD-10-CM Code	Description
D56.1	Beta thalassemia major and intermediate <ul style="list-style-type: none"> • Beta thalassemia major • Cooley's anemia • Homozygous beta thalassemia • Severe beta thalassemia • Thalassemia intermedia • Thalassemia major
D56.5	Hemoglobin E-beta thalassemia

ICD-10-CM Diagnosis Codes for MDS Associated Anemia⁶

ICD-10-CM Code	Description
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.4	Refractory anemia, unspecified
D46.Z	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

5010 Electronic Transaction Coding

- For electronic transactions, including 837P and 837I, the 11-digit NDC is to be preceded by the qualifier N4 for payers that require it⁷
- This is typically followed by the quantity qualifier, such as UN (units), F2 (international units), GR (gram), or ML (milliliter), and the quantity administered⁷

5010 Transaction Coding for REBLOZYL^{1,7}

How Supplied	NDC	NDC Qualifier	NDC Basis of Measurement	Sample NDC 5010 Format
25 mg lyophilized powder for solution for injection in a single-dose vial for reconstitution	59572-0711-01	N4	UN	N459572071101UN100
75 mg lyophilized powder for solution for injection in a single-dose vial for reconstitution	59572-0775-01	N4	UN	N459572077501UN300

The example given in the far-right column demonstrates NDC quantity reporting for 1 vial of REBLOZYL. The actual amount of drug used can vary based on factors such as patient weight. Currently, reporting NDC quantity varies from payer to payer, so the provider should consult each specific payer to determine the required format.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Coding and Billing Units

Please contact the payer or BMS Access Support® for additional information on coding and billing units

CMS-1500 Form: Physician Office Sample Claim Form

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. PAYER (Medicare, Medicaid, Tricare, etc.)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street)

6. PATIENT RELATIONSHIP TO INSURED

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE

14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP)

15. OTHER DATE

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE

17a. QUAL. 17b. NPI

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB?

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line to be billed)

22. RESUBMISSION CODE

23. PRIOR AUTHORIZATION NUMBER

24. A. DATES OF SERVICE From To B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER E. DIAGNOSIS POINTER F. \$ CHARGES G. DATE OF REFILL H. EFFECTIVE DATE I. Q. QUAL. J. RENDERING PROVIDER ID. #

25. FEDERAL TAX I.D. NUMBER SSN EIN

26. PATIENT'S ACCOUNT NO.

27. ACCEPT ASSIGNMENT? (For 9th-10th digit only)

28. TOTAL CHARGE \$

29. AMOUNT PAID \$

30. Reserved for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)

32. SERVICE FACILITY LOCATION INFORMATION

33. BILLING PROVIDER INFO & PH # ()

SIGNED DATE

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

A **Item 19:** Many payers require detailed information about the drug in Box 19.⁷ Typically, payers require the drug name, total dosage and strength, method of administration, 11-digit NDC, and basis of measurement

B **Item 21:** Enter the ICD-10-CM code⁷

C **Item 24A:** NDC information is required in the shaded area above the line on which a drug is reported in 24D.⁷ The NDC is preceded by the qualifier N4 and followed by the quantity qualifier (UN) and the quantity administered beginning in position 14.⁷ For example, use "N459572077501UN300" for one 75-mg vial¹

D **Item 24D:** Enter the appropriate HCPCS code (J0896) and appropriate CPT code(s)* for drug administration services; include modifiers, if applicable.^{2,3,7} In addition, it is required that you enter J0896-JW on next line to record waste

E **Item 24E:** Enter the diagnosis code reference letter or number from Box 21 that relates to the date of service and the services or procedures performed that is entered on that same line under 24D⁷

F **Item 24G:** Billing units are reported here.⁷ 0.25 mg = 1 billing unit³

This sample form is for informational purposes only.

- A claim for REBLOZYL should include the following³:
- A proper HCPCS code to define the drug and billing unit
 - The quantity of billing units provided to the patient
 - A CPT code that indicates how the physician administered the drug

In addition to coding specifics, some payers may require additional information, such as a drug purchase invoice or documentation of medical necessity.

*Any outpatient red blood cell transfusions given to address hemoglobin levels in patients with beta thalassemia or MDS entail their own set of HCPCS and CPT codes.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Coding and Billing Units (cont'd)

UB-04 Form (CMS-1450): Hospital Outpatient Department Sample Claim Form

- A Form Locator (FL 42):** Enter a 4-digit revenue code that best describes the service provided, in accordance with hospital billing policy.⁸ CMS recommends using revenue code 0636 (drugs requiring detailed coding)^{3,4}
- B FL 43:** Enter the modifier "N4" followed by the 11-digit NDC in positions 01-13.⁸ For example, use "N459572077501UN300" for one 75-mg vial^{1,8}
- C FL 44:** Enter HCPCS code (J0896) and code for the outpatient service (and modifier[s],* if applicable).^{2,3,8} In addition, it is required that you enter J0896-JW on next line to record waste
- D FL 46:** Billing units are called *service units* and are placed here.⁸ 0.25 mg = 1 billing unit³
- E FL 67:** Enter the ICD-10-CM diagnosis code⁸
- F FL 80:** Some payers require detailed information about the drug in FL 80.⁸ Typically, payers require the drug name, total dosage and strength, method of administration, 11-digit NDC, and basis of measurement

This sample form is for informational purposes only.

UB-04 is used for reimbursement of REBLOZYL administered in an institutional setting, such as a hospital, a clinic, or an ambulatory surgical center.⁸ Providers must submit a UB-04 claim form documenting the drug administered and associated services.

*Any outpatient red blood cell transfusions given to address hemoglobin levels in patients with beta thalassemia or MDS entail their own set of HCPCS and CPT codes and revenue codes. Certain level II HCPCS codes and CPT codes require the use of modifiers to improve coding accuracy.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration in Beta Thalassemia


REBLOZYL has 2 dose levels for patients with beta thalassemia¹

Assess and review the patient's Hgb and transfusion record prior to each administration

- If an RBC transfusion occurred prior to dosing, use the pretransfusion Hgb for dose evaluation
- If a patient experiences a dose delay due to Hgb increase, measure Hgb every week⁹

REBLOZYL dose titration for response¹

- Increase REBLOZYL dose with the goal of achieving reduction in transfusion burden, but do not increase if patient is experiencing adverse reactions. Discontinue REBLOZYL after 3 doses at the maximum dose if no transfusion burden reduction or if unacceptable toxicity occurs. Please see page 18 for Dosing Modifications for Adverse Reactions.



*Do not increase the dose if the patient is experiencing an adverse reaction as described in the Dose Modifications for Adverse Reactions table.

Hgb=hemoglobin; RBC=red blood cell.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration in Beta Thalassemia (cont'd)

Modifications for predose Hgb levels or rapid Hgb rise¹

Scenario	Dosing Recommendation
Predose Hgb is ≥11.5 g/dL in absence of transfusion	<ul style="list-style-type: none"> Interrupt treatment Restart at same dose when the Hgb is no more than 11 g/dL
Increase in Hgb >2 g/dL Within 3 Weeks in Absence of Transfusion and:	
Current dose is 1.25 mg/kg	<ul style="list-style-type: none"> Reduce dose to 1 mg/kg
Current dose is 1 mg/kg	<ul style="list-style-type: none"> Reduce dose to 0.8 mg/kg
Current dose is 0.8 mg/kg	<ul style="list-style-type: none"> Reduce dose to 0.6 mg/kg
Current dose is 0.6 mg/kg	<ul style="list-style-type: none"> Discontinue treatment

Hgb=hemoglobin.

Dose increase in the event of loss of response¹

- A dose increase to 1.25 mg/kg may occur at any time during treatment after patients have received at least 2 consecutive doses of 1 mg/kg
- Do not increase the dose beyond the maximum dose of 1.25 mg/kg**

Discontinue treatment if no reduction in transfusion burden is observed¹

- Discontinue REBLOZYL if a patient does not experience a decrease in transfusion burden after 3 doses (9 weeks of treatment) at the maximum dose level or if unacceptable toxicity occurs at any time

If a planned administration of REBLOZYL is delayed or missed¹


- Administer REBLOZYL as soon as possible and continue dosing as prescribed, with at least 3 weeks between doses

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration in MDS Associated Anemia ESA-naïve (1L)

Dose adjust to target hemoglobin of 10 to 12 g/dL¹



Discontinue if¹:

- After at least 3 consecutive doses (9 weeks) at 1.75 mg/kg, a patient has no reduction in transfusion burden including no increase from baseline Hgb

Loss of response¹:

- If, upon dose reduction, the patient loses response (eg, Hgb falls by 1 g/dL or more in 3 weeks in absence of transfusions or patient requires a transfusion), increase the dose by one dose level

Missed dose¹:

- Administer as soon as possible and continue treating with at least 3 weeks between doses

Before each dose: monitor Hgb, transfusion need, and tolerability.[‡]

See next page for additional dosing modifications. If patient is receiving 0.6 mg/kg and requires further dose reduction, discontinue treatment. For Grade 3/4 AE, pause until resolves to Grade 1 or lower, then resume at the next lower dose. If delay due to Grade 3/4 AE exceeds 12 consecutive weeks, discontinue treatment. Discontinue treatment for Grade 3/4 hypersensitivity.

^{*}Pre-dose hemoglobin in the absence of transfusions.¹

[†]If transfusion occurred, use pretransfusion Hgb before evaluation. Discontinue REBLOZYL if unacceptable toxicity occurs at any time.¹

Hgb=hemoglobin.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration in MDS Associated Anemia ESA-naïve (1L) (cont'd)

Dose modifications when administering REBLOZYL¹

Scenario	Dosing Recommendation
Predose Hgb is ≥12 g/dL in the absence of transfusion	<ul style="list-style-type: none"> Interrupt treatment Restart at same dose when the Hgb is less than or equal to 11 g/dL
Increase in Hgb >2 g/dL Within 3 Weeks in Absence of Transfusion and:	
Current dose is 1.75 mg/kg	<ul style="list-style-type: none"> Reduce dose to 1.33 mg/kg
Current dose is 1.33 mg/kg	<ul style="list-style-type: none"> Reduce dose to 1.0 mg/kg
Current dose is 1.0 mg/kg	<ul style="list-style-type: none"> Reduce dose to 0.8 mg/kg
Current dose is 0.8 mg/kg	<ul style="list-style-type: none"> Reduce dose to 0.6 mg/kg
Current dose is 0.6 mg/kg	<ul style="list-style-type: none"> Discontinue treatment


Hgb=hemoglobin.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration in MDS Associated Anemia RS+ ESA-refractory (2L)

Dose adjust to target hemoglobin of 10 to 11.5 g/dL



Before each dose: monitor Hgb, transfusion need, and tolerability.[†]

Please see page 18 for Dosing Modifications for Adverse Reactions.

*Predose hemoglobin in the absence of transfusions.¹

[†]If transfusion occurred, use pretransfusion Hgb before evaluation. Discontinue REBLOZYL if unacceptable toxicity occurs at any time.¹

Hgb=hemoglobin.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration in MDS Associated Anemia RS+ ESA-refractory (2L) (cont'd)

Dose modifications when administering REBLOZYL¹

Scenario	Dosing Recommendation
Predose Hgb is ≥12 g/dL in the absence of transfusion	<ul style="list-style-type: none"> Interrupt treatment Restart at same dose when the Hgb is less than or equal to 11 g/dL
Increase in Hgb >2 g/dL Within 3 Weeks in Absence of Transfusion and:	
Current dose is 1.75 mg/kg	<ul style="list-style-type: none"> Reduce dose to 1.33 mg/kg
Current dose is 1.33 mg/kg	<ul style="list-style-type: none"> Reduce dose to 1.0 mg/kg
Current dose is 1.0 mg/kg	<ul style="list-style-type: none"> Reduce dose to 0.8 mg/kg
Current dose is 0.8 mg/kg	<ul style="list-style-type: none"> Reduce dose to 0.6 mg/kg
Current dose is 0.6 mg/kg	<ul style="list-style-type: none"> Discontinue treatment

Hgb=hemoglobin.

Dose increase in the event of loss of response¹

- If, upon dose reduction, the patient loses response (ie, requires a transfusion) or Hgb concentration drops by 1 g/dL or more in 3 weeks in the absence of transfusion, increase the dose by 1 dose level
- Wait a minimum of 6 weeks between dose increases
- Dose increases to 1.33 mg/kg and subsequently to 1.75 mg/kg may occur at any time during treatment after patients have received at least 2 consecutive doses at the prior lower dose level
- Do not increase the dose more frequently than every 2 consecutive doses (6 weeks) or beyond the maximum dose of 1.75 mg/kg

Discontinue treatment if no clinical benefit is observed

- Discontinue REBLOZYL if no increase in Hgb or reduction in RBC transfusion burden from baseline after at least 3 consecutive doses (9 weeks) at 1.75 mg/kg or if unacceptable toxicity occurs at any time

If a planned administration of REBLOZYL is delayed or missed¹

- Administer REBLOZYL as soon as possible and continue dosing as prescribed, with at least 3 weeks between doses

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Dosage and Administration for REBLOZYL® (luspatercept-aamt)

Dose modifications for adverse reactions¹

Scenario	REBLOZYL Dosing Recommendation ^a
Grade 3 or 4 hypersensitivity reactions	<ul style="list-style-type: none"> Discontinue treatment
Other Grade 3 or 4 adverse reactions	<ul style="list-style-type: none"> Interrupt treatment Beta thalassemia: <ul style="list-style-type: none"> When the adverse reaction resolves to no more than Grade 1, restart treatment at the next lower dose level^b If the dose delay is greater than 15 consecutive weeks, discontinue treatment MDS associated anemia: <ul style="list-style-type: none"> When the adverse reaction resolves to no more than Grade 1, restart treatment at the next lower dose level^c If the dose delay is greater than 12 consecutive weeks, discontinue treatment
Extramedullary hematopoietic (EMH) masses causing serious complications	<ul style="list-style-type: none"> Beta thalassemia: Discontinue treatment

^aGrade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.

^bPer dose reductions in beta thalassemia dose titration for response table on page 13.

^cPer dose reductions in MDS dose titration for response table on page 15 and 17.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Medicare Drug Reimbursement

Coverage of REBLOZYL by Medicare is expected to follow guidance within chapter 15 of the *Medicare Benefit Policy Manual*, which states that “the program covers drugs that are furnished ‘incident to’ a physician’s service provided that the drugs are not usually self-administered by the patients who take them.”¹⁰ An injectable drug or biologic is typically eligible for inclusion under the “incident to” benefit when it is FDA approved, in a form not usually self-administered, furnished by a physician, and administered by the physician or by auxiliary personnel employed by the physician and under the physician’s personal supervision.¹⁰ It also can be furnished by other healthcare professionals.¹⁰ In addition, the drug must also be reasonable and necessary for an individual patient, as well as safe and effective.¹⁰

What is the Medicare reimbursement allowable for REBLOZYL?

Physicians*

- The payment limit is 106% of average sales price (ASP), not including sequestration, and represents 1 billing unit of REBLOZYL, which is billed for each 0.25 mg^{3,11†}
- The amount paid to providers is published at the beginning of each calendar quarter in “Payment Allowance Limits for Medicare Part B Drugs,”¹¹ which can be downloaded at <https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price>
- Medicare Part B will pay physicians 80% of the allowed price for REBLOZYL; the patient is responsible for 20% coinsurance, which may be covered by secondary insurance (private supplemental coverage, Medicaid, etc)¹²

Hospital outpatient facilities*

Drugs paid separately in the hospital outpatient setting are based on 106% of average sales price (ASP), not including sequestration, for 1 billing unit for the corresponding HCPCS code. This is 0.25 mg for REBLOZYL.^{3,11†}

- The Payment Allowance Limits¹¹ are published each quarter at <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice>

Hospital inpatient settings

- Reimbursement in the inpatient setting is bundled into the Medicare Diagnosis Related Groups called MS-DRGs^{13,14}
- This prospective rate does not allow for drugs to be paid separately¹⁵

* While the statutory amount that Medicare will reimburse for a Part B drug in a physician office will remain at ASP +6%, sequestration has resulted in a reduction to the Medicare portion of the payment to Medicare providers. Essentially, all payments from Medicare carriers to the providers (including physician offices, hospitals, etc) will be reduced by 2%.¹⁶

† See the Centers for Medicare & Medicaid Services’ (CMS) Internet Only Manual (IOM) Publication 100-04, Chapter 17-20.1.3.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Commercial Insurance Reimbursement

Physicians

- Drug reimbursement, like service reimbursement, is usually based on a fee schedule¹⁷
- The fee schedules are based on the ASP or AWP, as published by a credible source,^{18,19} or an average costing methodology as determined by the payer, such as usual, customary, and reasonable (UC&R)²⁰

Hospital outpatient facilities

- In this setting, reimbursement is most commonly based on percentage of charges¹⁹
- Alternatively, some hospitals use the same ASP or AWP methodologies typically used by physician offices¹⁹
- Other methodologies include capitated model, cost minus submitted charges, or discount off submitted charges¹⁹

Hospital inpatient settings

- Inpatient rates are prospective, meaning they are predetermined per discharge^{13,14}
- There are private payers that pay on a version of the DRGs¹⁴
- There are also payers that pay on a negotiated and fixed rate per day called a “per diem.”¹⁴ There are capitated rates for inpatients as well¹⁴
- New drugs may be carved out of per diems or capitated rates, if the hospital negotiates to do so²¹

Medicaid Insurance Reimbursement

Medicaid is a joint federal-state program that pays for medical assistance for individuals and families with low incomes and relatively few assets. Medicaid programs are established and administered by each individual state.²⁰ Although pharmacy coverage is an optional benefit under federal Medicaid law, all states currently provide coverage for outpatient prescription drugs to all categorically eligible individuals and most other enrollees within their state Medicaid programs.¹⁹ Benefits for Medicaid patients should be verified to identify additional needs such as prior authorizations.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Important Safety Information

WARNINGS AND PRECAUTIONS

Thrombosis/Thromboembolism

In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) of REBLOZYL-treated patients. TEEs included deep vein thrombosis, pulmonary embolus, portal vein thrombosis, and ischemic stroke. Patients with known risk factors for thromboembolism (splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients at increased risk of TEE. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly.

Hypertension

Hypertension was reported in 11.4% (63/554) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4 hypertension ranged from 2% to 9.6%. In patients with beta thalassemia with normal baseline blood pressure, 13 (6.2%) patients developed systolic blood pressure (SBP) \geq 130 mm Hg and 33 (16.6%) patients developed diastolic blood pressure (DBP) \geq 80 mm Hg. In ESA-refractory or -intolerant adult patients with MDS with normal baseline blood pressure, 26 (30%) patients developed SBP \geq 130 mm Hg and 23 (16%) patients developed DBP \geq 80 mm Hg. In ESA-naïve adult patients with MDS with normal baseline blood pressure, 23 (36%) patients developed SBP \geq 140 mm Hg and 11 (6%) patients developed DBP \geq 80 mm Hg. Monitor blood pressure prior to each administration. Manage new or exacerbations of preexisting hypertension using anti-hypertensive agents.

Extramedullary Hematopoietic (EMH) Masses

In adult patients with transfusion-dependent beta thalassemia, EMH masses were observed in 3.2% of REBLOZYL-treated patients, with spinal cord compression symptoms due to EMH masses occurring in 1.9% of patients (BELIEVE and REBLOZYL long-term follow-up study).

In a study of adult patients with non-transfusion-dependent beta thalassemia, a higher incidence of EMH masses was observed in 6.3% of REBLOZYL-treated patients vs. 2% of placebo-treated patients in the double-blind phase of the study, with spinal cord compression due to EMH masses occurring in 1 patient with a prior history of EMH. REBLOZYL is not indicated for use in patients with non-transfusion-dependent beta thalassemia.

Possible risk factors for the development of EMH masses in patients with beta thalassemia include history of EMH masses, splenectomy, splenomegaly, hepatomegaly, or low baseline hemoglobin ($<$ 8.5 g/dL). Signs and symptoms may vary depending on the anatomical location. Monitor patients with beta thalassemia at initiation and during treatment for symptoms and signs or complications resulting from the EMH masses and treat according to clinical guidelines. Discontinue treatment with REBLOZYL in case of serious complications due to EMH masses. Avoid use of REBLOZYL in patients requiring treatment to control the growth of EMH masses.

Embryo-Fetal Toxicity

REBLOZYL may cause fetal harm when administered to a pregnant woman. REBLOZYL caused increased post-implantation loss, decreased litter size, and an increased incidence of skeletal variations in pregnant rat and rabbit studies. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose.

ADVERSE REACTIONS

Please see [U.S. Full Prescribing Information for REBLOZYL](#).

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Important Safety Information (cont'd)

Beta-Thalassemia

Serious adverse reactions occurred in 3.6% of patients on REBLOZYL. Serious adverse reactions occurring in 1% of patients included cerebrovascular accident and deep vein thrombosis. A fatal adverse reaction occurred in 1 patient treated with REBLOZYL who died due to an unconfirmed case of acute myeloid leukemia (AML).

Most common adverse reactions (at least 10% for REBLOZYL and 1% more than placebo) were headache (26% vs 24%), bone pain (20% vs 8%), arthralgia (19% vs 12%), fatigue (14% vs 13%), cough (14% vs 11%), abdominal pain (14% vs 12%), diarrhea (12% vs 10%) and dizziness (11% vs 5%).

ESA-naïve adult patients with Myelodysplastic Syndromes

Grade >3 (>2%) adverse reactions included hypertension and dyspnea.

The most common (>10%) all-grade adverse reactions included diarrhea, fatigue, hypertension, peripheral edema, nausea, and dyspnea.

ESA-refractory or -intolerant adult patients with Myelodysplastic Syndromes

Grade ≥ 3 ($\geq 2\%$) adverse reactions included fatigue, hypertension, syncope and musculoskeletal pain. A fatal adverse reaction occurred in 5 (2.1%) patients.

The most common ($\geq 10\%$) adverse reactions included fatigue, musculoskeletal pain, dizziness, diarrhea, nausea, hypersensitivity reactions, hypertension, headache, upper respiratory tract infection, bronchitis, and urinary tract infection.

LACTATION

It is not known whether REBLOZYL is excreted into human milk or absorbed systemically after ingestion by a nursing infant. REBLOZYL was detected in milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because many drugs are excreted in human milk, and because of the unknown effects of REBLOZYL in infants, a decision should be made whether to discontinue nursing or to discontinue treatment. Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for 3 months after the last dose.

DRUG ABUSE POTENTIAL

Abuse: Abuse of REBLOZYL may be seen in athletes for the effects on erythropoiesis. Misuse of drugs that increase erythropoiesis, such as REBLOZYL, by healthy persons may lead to polycythemia, which may be associated with life-threatening cardiovascular complications.

Please see [U.S. Full Prescribing Information for REBLOZYL](#).

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

References

1. REBLOZYL [package insert]. Summit, NJ: Celgene Corp; 2026.
2. American Medical Association. HCPCS Level II Expert 2025. American Medical Association; 2024.
3. Medicare Claims Processing Manual. Chapter 17 – Drugs and Biologicals Revision 13255, June 6, 2025. Accessed December 11, 2025. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c17.pdf>.
4. National Uniform Billing Committee (NUBC). Official UB-04 Data Specifications Manual 2026. American Hospital Association; 2025.
5. American Medical Association. CPT 2025 Professional Edition. American Medical Association; 2024.
6. American Medical Association. ICD-10-CM Expert 2025. American Medical Association; 2024.
7. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Chapter 26 – Completing and Processing Form CMS-1500 Data Set. Revision 12779, August 9, 2024. Accessed December 11, 2025. <http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c26.pdf>.
8. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Chapter 25 – Completing and Processing the Form CMS-1450 Data Set. Revision 12423, December 20, 2023. Accessed December 11, 2025. <http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c25.pdf>.
9. Data on file. Celgene Corporation. Summit, New Jersey.
10. Centers for Medicare & Medicaid Services. Medicare Benefit Policy Manual. Chapter 15 – Covered Medical and Other Health Services. Revision 13108, April 11, 2025. Accessed December 11, 2025. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
11. Centers for Medicare & Medicaid Services. October 2025 ASP drug pricing files. Updated September 19, 2025. Accessed July 17, 2023. <https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files>.
12. Centers for Medicare & Medicaid Services. Your Medicare Benefits. CMS product number 10116. April 2025. Accessed December 12, 2025. <https://www.medicare.gov/Pubs/pdf/10116-Your-Medicare-Benefits.pdf>.
13. Centers for Medicare & Medicaid Services. Acute inpatient PPS. Updated August 4, 2025. Accessed December 12, 2025. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index?redirect=/acuteinpatientpps>.
14. Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods, executive edition, version 3.0; 2013. Revised April 2013. Accessed December 13, 2025. <https://www.amcp.org/sites/default/files/2019-03/Full-Pharmaceutical-Guide-%283.0%29.pdf>.
15. Centers for Medicare & Medicaid Services. Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates. Federal Register. 90 FR 36536. August 4, 2025. Accessed December 12, 2025. <https://www.federalregister.gov/documents/2025/08/04/2025-14681/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipsps-and>.
16. Mandatory payment reductions in the Medicare Fee-for-Service (FFS) program—“sequestration.” News release. Medical Learning Network, Centers for Medicare & Medicaid Services CMS Medicare FFS Provider e-News; March 8, 2013. Accessed December 12, 2025. <https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Downloads/2013-03-08-standalone.pdf>.
17. Robinson JC. Insurers' strategies for managing the use and cost of biopharmaceuticals. *Health Aff (Millwood)*. 2006;25(5):1205-1217.
18. American Society of Clinical Oncology. Payment reform glossary. ASCO website. <https://www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/pdf/Payment-Reform-Glossary.pdf>.
19. Magellan Rx Management. Medical Pharmacy Trend Report 2016. <http://www.magellanrxinsights.com>.
20. US Bureau of Labor Statistics. Definitions of health insurance terms. <http://www.bls.gov/ncs/ebs/sp/healthterms.pdf>.
21. Academy of Managed Care Pharmacy. Managed care glossary. Accessed December 12, 2025. <https://www.amcp.org/about/managed-care-pharmacy-101/managed-care-glossary>.

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).

For reimbursement assistance, call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET, Monday–Friday, or visit www.BMSAccessSupport.com.

Looking for support? We're here for you.

Coverage assistance, educational resources, and financial support options may be available through **BMS Access Support®**



Call a Patient Access Specialist at
1-800-861-0048, 8 AM to 8 PM ET,
Monday-Friday



Visit
www.BMSAccessSupport.com



Schedule a meeting
with a BMS Access and
Reimbursement Manager on the
BMS Access Support website

Please see [Important Safety Information](#) on pages 21-22 and [U.S. Full Prescribing Information](#).